RA0699

antibody from Oursmab

Targeting: SOST DAND6, VBCH

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0699

Provider

Oursmab

Product name

Blosozumab (Biosimilar Reference Antibody) (SOST)

Antibody type

Monoclonal

Description

Blosozumab is a humanized monoclonal antibody designed to target and inhibit sclerostin (SOST), a key negative regulator of bone formation. Sclerostin, primarily produced by osteocytes, acts by binding to low-density lipoprotein receptor-related proteins 5 and 6 (LRP5/6), thereby antagonizing the canonical Wnt/¦Â-catenin signaling pathway that is essential for osteoblast differentiation and activity. By neutralizing sclerostin, blosozumab aims to promote bone formation, increase bone mineral density (BMD), and enhance bone strength. It was investigated as a potential anabolic (bone-building) therapy for osteoporosis, demonstrating significant increases in BMD in Phase I and II clinical trials. However, its development for postmenopausal osteoporosis was discontinued in favor of another anti-sclerostin antibody, romosozumab, which later received regulatory approval.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.